Matthew White
Director of Finance/CFO at APIAM ANIMAL HEALTH LIMITED
Net worth: 33 988 $ as of 30/05/2024
Matthew White active positions
| Companies | Position | Start | End |
|---|---|---|---|
| APIAM ANIMAL HEALTH LIMITED | Director of Finance/CFO | 31/07/2015 | - |
Career history of Matthew White
Former positions of Matthew White
| Companies | Position | Start | End |
|---|---|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
 Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Director of Finance/CFO | - | - |
Statistics
International
| Australia | 3 |
Operational
| Director of Finance/CFO | 2 |
Sectoral
| Distribution Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| APIAM ANIMAL HEALTH LIMITED | Distribution Services |
| Private companies | 1 |
|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
- Stock Market
- Insiders
- Matthew White
- Experience